litlas
Log inCreate account

Richard Greil

Active 1989–2026

274
Papers
38,814
Citations
104
h-index
257
i10-index

Citations

Citations per year for Richard Greil1948: 1 citations1990: 3 citations1991: 1 citations1992: 1 citations1993: 5 citations1995: 1 citations1996: 1 citations1997: 2 citations1998: 13 citations1999: 7 citations2000: 12 citations2001: 21 citations2002: 33 citations2003: 30 citations2004: 26 citations2005: 40 citations2006: 51 citations2007: 64 citations2008: 74 citations2009: 101 citations2010: 136 citations2011: 184 citations2012: 186 citations2013: 243 citations2014: 234 citations2015: 275 citations2016: 236 citations2017: 254 citations2018: 239 citations2019: 863 citations2020: 1,264 citations2021: 1,348 citations2022: 1,360 citations2023: 1,126 citations2024: 2,060 citations2025: 1,065 citations2026: 26 citations1949–1989: no citations, so these years are not shown1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,908 citing papers, 21.3% of this breakdownChina: 1,520 citing papers, 8.3% of this breakdownItaly: 1,311 citing papers, 7.2% of this breakdownGermany: 1,219 citing papers, 6.6% of this breakdownUnited Kingdom: 1,094 citing papers, 6% of this breakdownFrance: 844 citing papers, 4.6% of this breakdownSpain: 695 citing papers, 3.8% of this breakdownCanada: 617 citing papers, 3.4% of this breakdownSwitzerland: 582 citing papers, 3.2% of this breakdownAustralia: 530 citing papers, 2.9% of this breakdownJapan: 524 citing papers, 2.9% of this breakdownNetherlands: 455 citing papers, 2.5% of this breakdown
0%21.3%Other 27.3%

Institutions

Fields

  • Medicine71.2%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Immunology and Microbiology3.8%
  • Neuroscience0.5%
  • Agricultural and Biological Sciences0.5%
  • Engineering0.5%
  • Other2.2%

Topics

  • Cancer Immunotherapy and Biomarkers5.5%
  • Lymphoma Diagnosis and Treatment3.7%
  • Breast Cancer Treatment Studies3.3%
  • CAR-T cell therapy research3%
  • HER2/EGFR in Cancer Research2.7%
  • Chronic Lymphocytic Leukemia Research2.4%
  • Other79.4%

Coauthors

All papers

Open in search
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    Authors: Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi and 119 more - The Lancet 2019 cited by 3,211

  2. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    Authors: Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný, Jeff P. Sharman, Charles Herbaux, John M. Burke, Matthew Matasar, Shinya Rai, Koji Izutsu, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Richard Greil, Larysa Mykhalska, Juan M. Bergua-Burgués, Matthew C. Cheung, Antonio Pinto, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Jamie Hirata, Yanwen Jiang, Mark Yan, Calvin Lee, Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 cited by 843

  3. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

    Authors: Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Irene Braña, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gümüşçü, Ramona F. Swaby, Danny Rischin - Journal of Clinical Oncology 2022 cited by 490

  4. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Authors: Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang, Daniel Egle, Maurizio Callari, Begoña Bermejo, Matteo Dugo, Claudio Zamagni, Marc Thill, Anton Anton, Stefania Zambelli, Stefania Russo, Eva Ciruelos, Richard Greil, Balázs Győrffy, Vladimir Semiglazov, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Biasi, Robert S. Seitz, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini, H. Raza Ali - Nature 2023 cited by 325

  5. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Authors: Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross, Priya Rastogi, Karen Cui, Amal Arahmani, Gursel Aktan, Anne Armstrong, Mónica Arnedos, Judith Balmaña, Jonas Bergh, Judith M. Bliss, Suzette Delaloge, Susan M. Domchek, Andrea Eisen, F. Elsafy, L.E. Fein, Anitra Fielding, James M. Ford, Sue Friedman, Karen A. Gelmon, Luca Gianni, Michael Gnant, Simon J. Hollingsworth, Seock‐Ah Im, Agnes Jager, Oskar T. Johannsson, Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447

  6. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    Authors: Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian W. Flinn, Werner Rabitsch, Yok‐Lam Kwong, Marie José Kersten, Monique C. Minnema, Harald Holte, Esther Hian Li Chan, Joaquín Martínez‐López, Antonia Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David A. Bond, Charalambos Andreadis, Peter A. McSweeney, Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 cited by 520

  7. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    Authors: Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, I. Maffeis, Pinuccia Valagussa, Giuseppe Viale - Annals of Oncology 2022 cited by 386

  8. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Authors: Vivek Subbiah, Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle, Filippo de Braud, Gerald W. Prager, Richard Greil, Alexander Stein, Angelica Fasolo, Jan H.M. Schellens, Patrick Y. Wen, Kert Viele, Aislyn Boran, Eduard Gasal, Paul Burgess, Palanichamy Ilankumaran, Zev A. Wainberg - The Lancet Oncology 2020 cited by 518

  9. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    Authors: Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepłuch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen - The Lancet Oncology 2022 cited by 278

  10. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Authors: Michael Gnant, Amylou C. Dueck, Sophie Frantal, Miguel Martín, H.J. Burstein, Richard Greil, Peter Fox, Antonio C. Wolff, Arlene Chan, Eric P. Winer, Georg Pfeiler, Kathy D. Miller, Marco Colleoni, Jennifer M. Suga, Gabor Rubovsky, Judith M. Bliss, Ingrid A. Mayer, Christian F. Singer, Zbigniew Nowecki, Olwen Hahn, Jacqui Thomson, Norman Wolmark, Kepa Amillano, Hope S. Rugo, Guenther G. Steger, Blanca Hernando Fernández de Aranguiz, Tufia C. Haddad, Antonia Perelló, Meritxell Bellet, Hannes Fohler, Otto Metzger, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, K. P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer, on behalf of the PALLAS groups and investigators - Journal of Clinical Oncology 2021 cited by 231

  11. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

    Authors: Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae‐Lyun Lee, Niven Mehra, Ray McDermott, Núria Sala‐González, Peter C.C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Rustem Gafanov, Maria De Santis, Eli Rosenbaum, Michael Kolinsky, Felipe Rey, Kun‐Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian Poehlein, Evan Y. Yu - Journal of Clinical Oncology 2023 cited by 132

  12. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    Authors: Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo Vasconcelos Alves, Iane Pinto Figueiredo Lima, Brett Hughes, Y. Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean‐Pierre Delord, Ricard Mesı́a, Miren Taberna, John Waldron, Christian Simon, Vincent Grégoire, Kevin J. Harrington, Ramona F. Swaby, Yayan Zhang, Burak Gümüşçü, Behzad Bidadi, Lillian L. Siu, Danny Rischin, Brett Hughes, Bo Gao, Margaret McGrath, Richard Greil, Dietmar Thurnher, Thorsten Fuereder, Martin Burian, Sylvie Rottey, Jean‐Pascal Machiels, Paul Clement, Stéphanie Henry, S. Deheneffe, Gustavo Vasconcelos Alves, Iane Pinto Figueiredo Lima, Josiane Mourão Dias, Pedro Rafael Martins De Marchi, Milena Perez Mak, Andrea Juliana Gomes, Dalvaro Oliveira de Castro Junior, Tatiane Cardoso Motta, Mônica Luciana Agostinho Padoan, Ana Paula Victorina, Sérgio Jobim Azevedo, Lillian L. Siu, Stephanie Yasmin Brule, John Hilton, Chang Shu Wang, Nathaniel Bouganim, Marc Webster, John Walker, Neil Chua, Ángela R. Zambrano, Alicia Quiroga Echeverri, Oscar Mauricio Niño Gomez, Carlos Alberto Ortiz, Luis Alejandro Rojas, Andrés Cardona Zorilla, Olga Marcela Urrego Meléndez, Petra Holečková, Bohuslav Melichar, Jakub Cvek, Jana Prausová, Milan Vošmik, Jean‐Pierre Delord, Xavier Zasadny, Lionnel Geoffrois, Yungan Tao, Y. Pointreau, Rainer Fietkau, Marlen Haderlein, Andreas Müller, Ursula C. Schroeder, Barbara Wollenberg, Simon Laban, Philipp Ivanyi, Viktor Gruenwald, Philippe Schafhausen, Orit Gutfeld, Iris Gluck, Aron Popovtzer, Amichay Meirovitz, Salem Billan, Baruch Brenner, Aron Popovtzer, Dror Limon, Lisa Licitra, Francesco Perri, Francesco Caponigro, Martina Violati, Daris Ferrari, Franco Nolè, Federica Bertolini and 90 more - The Lancet Oncology 2024 cited by 210

  13. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

    Authors: Barbara Burtness, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G.M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Ge, Ramona F. Swaby, Burak Gumuscu, Kevin Harrington - Journal of Clinical Oncology 2022 cited by 207

  14. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

    Authors: Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, José María Viéitez, Olivier Bouché, Christophe Borg, Claus-Christoph Steffens, Vicente Alonso-Orduña, C. Schlichting, Irmarie Reyes‐Rivera, Belguendouz Bendahmane, Thierry André, Stefan Kubicka - The Lancet Oncology 2012 cited by 1,164

  15. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

    Authors: Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva, Miklós Egyed, Viktor Rossiev, Petr Ďulíček, Árpád Illés, Halyna Pylypenko, Lylia Sivcheva, Jiřı́ Mayer, Vera Yablokova, Kurt Krejcy, Barbara Grohmann-Izay, Hans Carl Hasselbalch, Róbert Královics, Jean‐Jacques Kiladjian, F. Samuel Bauer, Nicoleta P. Berbec, Carlos Besses Raebel, Zita Borbényi, Horia Bumbea, Veronika Buxhofer‐Ausch, Małgorzata Całbecka, Emilie Cayssials-Caylus, Mario Cazzola, O Cerná, Andrei Cucuianu, Delia Dima, Ernst Forjan, Emanuil Gheorghita, Richard Greil, Antónia Hatalova, M Hrubisko, János Jakucs, Polina Kaplan, Sergiy Klymenko, Steffen Koschmieder, Mihaela Lazaroiu, Tamila Lysa, Zvenyslava Masliak, Tamás Masszi, Georgi Mihaylov, Alexander Myasnikov, Uwe Platzbecker, Mathieu Puyade, Jérôme Rey, Lydia Roy, Jiřı́ Schwarz, Aleksander B. Skotnicki, I. Ya. Sokolova, Maria Soroka‐Wojtaszko, Jolanta Starzak-Gwóźdź, Vera Stoeva, Jose Miguel Torregrosa‐Diaz, Anna Vallova, Elena Volodicheva, Krzysztof Warzocha, Ella Willenbacher, Dominik Wolf‎ - The Lancet Haematology 2020 cited by 347

  16. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by Programmed Death Ligand-1 combined positive score

    Authors: Barbara Burtness, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Castro, Gilberto de, Amanda Psyrri, Irene Braña, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Mesía Nin, Ricard, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Yang Ge, Ramona F. Swaby, Burak Gümüşçü, Kevin J. Harrington - 2022 cited by 177

  17. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  18. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

    Authors: Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, Debora Fumagalli, Christos Sotiriou, Einav Nili Gal‐Yam, Mark E. Robson, Justin Ndozeng, Angelo Di Leo, Eva Ciruelos, Evandro de Azambuja, Giuseppe Viale, Elsemieke D. Scheepers, Giuseppe Curigliano, Judith M. Bliss, Jorge S. Reis‐Filho, Marco Colleoni, Marija Balić, Fátima Cardoso, Joan Albanell, Caroline Duhem, Sandrine Marréaud, Dario Romagnoli, Beatriz Rojas, Andrea Gombos, Hans Wildiers, Ángel Guerrero‐Zotano, Peter S Hall, Andrea Bonetti, Karolina Larsson, Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart - Cancer Discovery 2021 cited by 177

  19. CAR T-Cell Therapy in Hematological Malignancies

    Authors: Theresa Haslauer, Richard Greil, Nadja Zaborsky, Roland Geisberger - International Journal of Molecular Sciences 2021 cited by 174

  20. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

    Authors: Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis, Nicolas Girard, Vipul M. Patel, Takayuki Takahama, Scott Owen, Douglas Reznick, Firas Badin, İrfan Çiçin, Sabeen Mekan, Riddhi Patel, Éric Zhang, Divyadeep Karumanchi, Marina Chiara Garassino, Elizabeth Ahern, Venessa Chin, Stephen Della‐Fiorentina, Kevin Jasas, Christos S. Karapetis, Jeremy Long, Louise Nott, Kenneth J. O’Byrne, Craig Underhill, Richard Greil, Maximilian J. Hochmair, Andreas Pircher, Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan A. Azambuja, Giuliano Santos Borges, Gilberto de Castro, Suellen Castro, Felipe Melo Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert H. El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier-Valette, Jaafar Bennouna, C. Chouaïd, Alexis B. Cortot, S. Couraud, D. Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux‐Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, J. Madelaine, M. Marcq, E. Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, A. Vergnenègre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Αthanasios Kotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Bettini, Matteo Brighenti, Giulio Cerea, Filippo de Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Héctor Soto Parrà, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi and 101 more - Journal of Clinical Oncology 2024 cited by 115

  21. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    Authors: Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromı́r Roubec, Luboš Petruželka, Libor Havel, Sujith Kalmadi, Jeffrey P. Ward, Zoran Andrić, Thierry Berghmans, David E. Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim G.J.V. Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Christian Rolfo, Wallace Akerley, Michael Eaton, Mussawar Iqbal, Corey J. Langer - The Lancet Oncology 2023 cited by 101

  22. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    Authors: Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Šimkovič, Olga Samoilova, Jan Novák, Dina Ben‐Yehuda, Владимир Стругов, Devinder Gill, John G. Gribben, Emily Hsu, Chih‐Jian Lih, Cathy Zhou, Fong Clow, Danelle F. James, Lori Styles, Ian W. Flinn - The Lancet Oncology 2018 cited by 548

  23. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

    Authors: Claudia Zelle‐Rieser, Shanmugapriya Thangavadivel, R. Biedermann, Andrea Brunner, Patrizia Stoitzner, Ella Willenbacher, Richard Greil, Karin Jöhrer - Journal of Hematology & Oncology 2016 cited by 327

  24. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

    Authors: Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-François Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles Salles, Marek Trněný, Sven de Vos, Farheen Mir, Divya Samineni, Su Y. Kim, Yanwen Jiang, Elizabeth A. Punnoose, Arijit Sinha, Emma Clark, Nathalie Spielewoy, Kathryn Humphrey, Alexandra Bazeos, Andrew D. Zelenetz - Blood 2020 cited by 169